VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

VYNE Therapeutics Inc. (VYNE) Total Return Calculator with Dividends Reinvested

VYNE Therapeutics Inc.

Popular:

The total return for VYNE Therapeutics Inc. (VYNE) stock is -50.40% over the past 12 months. So far it's up 15.45% this year. The 5-year total return is -98.96%, meaning $10,000 invested in VYNE stock 5 years ago would be worth $104 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in VYNE 1 year ago, it would be worth $4,888 today — you'd have lost $5,112.

With Dividends Reinvested$4,888-51.12%

Price Only (No DRIP)$4,888-51.12%

Period2025-05-07 → 2026-05-06

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in VYNE

1Y$4,960-$5,040 (-50.4%)-50.4% CAGR

3Y$773-$9,227 (-92.3%)-57.4% CAGR

5Y$104-$9,896 (-99.0%)-59.8% CAGR

10Y$3-$9,997 (-100.0%)-55.2% CAGR

15Y$3-$9,997 (-100.0%)-41.5% CAGR

20Y$3-$9,997 (-100.0%)-33.1% CAGR

30Y$3-$9,997 (-100.0%)-23.5% CAGR

VYNE Therapeutics Inc. did not pay dividends during this period. Total return = price return.

Loading VYNE total return...

As of 2026-05-07

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+15.45%	—	+15.45%	—	$11,545
1Y	-50.40%	-50.40%	-50.40%	—	$4,960
3Y	-92.27%	-57.40%	-92.27%	—	$773
5Y	-98.96%	-59.84%	-98.96%	—	$104
10Y	-99.97%	-55.22%	-99.97%	—	$3
15Y	-99.97%	-41.47%	-99.97%	—	$3
20Y	-99.97%	-33.08%	-99.97%	—	$3
30Y	-99.97%	-23.50%	-99.97%	—	$3

Risk & Highlights

Best Year+46.93%2024

Worst Year-86.73%2022

Max Drawdown-83.79%2025-07-01 → 2025-09-09

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+3.52%	+3.52%	—	+0.41%	+3.1pp
2025	-82.58%	-82.58%	—	+16.64%	-99.2pp
2024	+46.93%	+46.93%	—	+24.00%	+22.9pp
2023	-5.67%	-5.67%	—	+24.81%	-30.5pp
2022	-86.73%	-86.73%	—	-19.95%	-66.8pp

VYNE underperformed the S&P 500 by 81.72pp over the past year (-50.40% vs +31.32%).

Loading summary...

VYNE Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
VYNEVYNE Therapeutics Inc.	$29M	+8.4%	+15.4%	-50.4%	—	-92.3%	-99.0%	-100.0%
DERMJourney Medical Corporation	$106M	+7.2%	-30.1%	-19.8%	—	+215.8%	-45.2%	-45.2%
PRGOPerrigo Company plc	$1.7B	+15.8%	-9.6%	-45.6%	+4.7pp	-56.6%	-58.6%	-76.8%
SKINThe Beauty Health Company	$121M	+4.5%	-33.4%	-11.2%	—	-91.5%	-92.7%	-91.4%
ORGOOrganogenesis Holdings Inc.	$325M	+14.3%	-44.8%	-50.8%	—	+19.1%	-87.6%	-73.7%
GDRXGoodRx Holdings, Inc.	$881M	+24.2%	-6.5%	-39.7%	—	-44.3%	-92.7%	-94.9%
NKTRNektar Therapeutics	$1.7B	+13.9%	+96.0%	+783.6%	—	+636.7%	-69.4%	-57.6%
PCRXPacira BioSciences, Inc.	$932M	+6.4%	-3.1%	-5.8%	—	-43.9%	-62.5%	-50.0%
INVAInnoviva, Inc.	$1.9B	-2.2%	+13.3%	+20.4%	—	+92.8%	+95.5%	+90.5%
AMRXAmneal Pharmaceuticals, Inc.	$4.3B	+10.3%	+7.6%	+89.7%	—	+574.3%	+135.6%	-54.3%
MCKMcKesson Corporation	$91.1B	-13.2%	-9.6%	+5.0%	+0.4pp	+104.0%	+308.4%	+351.9%

Compare:VYNE vs DERM VYNE vs PRGO VYNE vs SKIN VYNE vs DERM vs PRGO

About VYNE Dividend Returns

VYNE Therapeutics Inc. (VYNE) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of VYNE over the past year?

VYNE Therapeutics Inc. (VYNE) delivered a return of -50.40% over the past year. Since VYNE does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in VYNE be worth today?

A $10,000 investment in VYNE Therapeutics Inc. one year ago would be worth $4,960 today, representing a loss of $5,040.

Q3Does VYNE pay dividends?

VYNE Therapeutics Inc. (VYNE) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For VYNE, the total return equals the price-only return.

Q4Did VYNE beat the S&P 500?

No, VYNE Therapeutics Inc. (VYNE) underperformed the S&P 500 by 81.72 percentage points over the past year. VYNE delivered a total return of -50.40%, compared to the S&P 500's 31.32%. This means a passive S&P 500 index fund outperformed VYNE by 81.72pp during this period.

Q5What is VYNE's worst drawdown?

VYNE Therapeutics Inc. (VYNE) experienced a maximum drawdown of -83.79% over the past year, declining from its peak on 2025-07-01 to its trough on 2025-09-09. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is VYNE's long-term total return over 10, 20, or 30 years?

Here are VYNE Therapeutics Inc. (VYNE)'s long-term returns with dividends reinvested. Over 10 years, the total return is -100.0% (-55.2% CAGR) — $10,000 would have grown to $3. Over 20 years: -100.0% total return (-33.1% CAGR) — $10,000 → $3. Over 30 years: -100.0% total return (-23.5% CAGR) — $10,000 → $3. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was VYNE's best and worst year?

VYNE Therapeutics Inc.'s best calendar year was 2024 with a total return of 46.9%. Its worst year was 2022 with a total return of -86.7%. This range shows the volatility investors should expect — the difference between the best and worst year is 133.7 percentage points.